Phase 1 × Neoplasm Metastasis × CNS × Clear all
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
NCT03911388 2026-02-17

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
155 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT00784914 2018-04-17

A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors

City of Hope Medical Center

Phase 1 Completed
12 enrolled
NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
NCT00002647 2013-09-20

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors

National Cancer Institute (NCI)

Phase 1 Unknown
24 enrolled
NCT00544284 2013-02-15

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

City of Hope Medical Center

Phase 1 Completed
25 enrolled
NCT00023790 2011-08-24

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Case Comprehensive Cancer Center

Phase 1 Terminated
3 enrolled
NCT00006246 2009-10-07

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

Pediatric Brain Tumor Consortium

Phase 1 Completed
28 enrolled
NCT00120939 2009-04-03

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

Pharmacyclics LLC.

Phase 1 Completed
25 enrolled